Pfizer PFE.N, in a conference call with industry analysts: • Says bococizumab at 52 weeks showed waning potency against LDL cholesterol in substantial number of patients • Says disappointing trend at 52 weeks for bococizumab contrasted with robust efficacy seen at 12 weeks and 24 weeks • Says waning efficacy of bococizumab likely was caused by neutralizing impact of naturally occuring antibodies • Pfizer CEO says company aims to increase its involvement with cardiovascular drugs, including through acquisitions • Pfizer CEO says remains interested in acquisitions, with no limit on size of potential deals • Pfizer research chief says company aims to become a leader in combination therapies involving immuno-oncology drugs
Market Data 
Markets 
AI
